Barclays analyst Jeanine Wai downgrades APA (NASDAQ:APA) from Overweight to Equal-Weight and raises the price target from $20 to $25.
Moderna Announced Plants to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year at the 50 µg dose level.
